Single dose pharmacokinetic study of HP-3060

Single dose pharmacokinetic study of HP-3060 in pediatric patients with allergic rhinitis (2)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223788

Enrollment

Registered

2018-01-29

Start date

2018-01-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

investigational material(s) Generic name etc : emedastine fumarate INN of investigational material : emedastine Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients who a diagnosis of allergic rhinitis and symptoms of this condition.

Exclusion criteria

Exclusion criteria: - Patients who have a history of hypersensitivity to any medicines. - Patients who may be affected by blood sampling in the study following blood collection or bleeding within 4 weeks prior to study drug administration.

Design outcomes

Primary

Measure	Time frame
safety Pharmacokinetics, Safety (adverse event)	—

Secondary

Measure	Time frame
safety Safety (laboratory data)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026